Cingulate INC

Cingulate Inc. announced the elimination of its Chief Legal Officer position, with Nilay Patel departing effective August 3, 2026.

Cingulate Inc. announced key stockholder approvals at its 2026 Annual Meeting, including an amendment to its equity incentive plan and changes to its Board of Directors structure.

Cingulate Inc. announced its inclusion in the Russell 3000E Index and an extension of its Chief Medical Officer's trial employment period.

Cingulate Inc. announced the issuance of a U.S. patent for its lead ADHD asset, CTx-1301, extending exclusivity for its formulation and method of use through December 2042.

Cingulate Inc. announced the FDA issued a Complete Response Letter for its ADHD drug candidate CTx-1301, citing CMC-related requests without clinical concerns.

Cingulate Inc. announces board size reduction and director re-appointments ahead of the 2026 Annual Meeting.

Cingulate Inc. reported a net loss of $9.3 million for Q1 2026, with significant increases in general and administrative expenses, while maintaining sufficient cash for operations into early 2027.

Cingulate Inc. reported a significantly wider net loss in Q3 2025 as R&D and administrative expenses surged, while its lead ADHD drug CTx-1301 advanced to FDA review despite ongoing liquidity concerns and recent management turmoil.

Cingulate Inc. reported increased net losses and a going concern warning, while successfully submitting its lead ADHD drug NDA and undergoing significant management restructuring.

Cingulate Inc. announces its financial results for the first quarter of 2025, highlighting ongoing development of its ADHD and anxiety treatments and providing a business update.

Cingulate Inc. announced its third quarter 2024 financial results, highlighting progress in clinical development and strategic financial activities.

Cingulate Inc. reported its financial results for the second quarter of 2024, highlighting a decrease in operating expenses and providing updates on its clinical programs and recent capital raising activities.

Cingulate Inc.'s 2024 10-K filing details the company's financial status, clinical development plans, and regulatory strategies for its ADHD and anxiety product candidates.

Cingulate Inc.'s 10-K filing outlines its capital structure, including common and preferred stock, warrants, and compliance with Delaware law and SEC regulations.

Shane J. Schaffer, Chief Executive Officer and a Director of Cingulate Inc., reported multiple transactions in common stock on July 16, 2026.

Bryan Wade Downey, EVP & Chief Commercial Officer of Cingulate Inc., reported multiple transactions in common stock on July 16, 2026.

Bryan Jay Lawrence, a Director of Cingulate Inc., received 20,000 shares of common stock on July 16, 2026.

Matthew Brams, EVP and Chief Medical Officer of Cingulate Inc., reported multiple transactions in common stock on July 16, 2026.

Thomas Jeffrey Hargroves, a Director of Cingulate Inc., received 20,000 shares of common stock on July 16, 2026.

Jennifer L. Callahan, EVP and CFO of Cingulate Inc., reported multiple transactions in common stock on July 16, 2026.

Cingulate Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held on July 9, 2026.

Cingulate Inc. calls a Special Meeting to approve the conversion of preferred stock and exercise of warrants from a recent $12 million private placement, crucial for Nasdaq compliance and future capital.

Cingulate Inc. is calling a special stockholder meeting to approve the issuance of over 20% of its common stock to Lincoln Park Capital Fund, LLC, enabling access to up to $25 million in capital.

Cingulate Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Cingulate Inc. is asking stockholders to approve a reverse stock split and an amendment to its equity incentive plan at the upcoming annual meeting.

Cingulate Inc. has adjourned its Special Meeting of Stockholders to August 28, 2024, due to the absence of a quorum, urging stockholders to vote on the proposals.

Cingulate Inc. has entered into a new $25 million committed equity financing agreement with Lincoln Park Capital Fund, LLC to fund its biopharmaceutical pipeline, including the anticipated NDA submission for its lead ADHD candidate, CTx-1301.

Cingulate Inc. has entered into a new $25 million committed equity financing agreement with Lincoln Park Capital Fund, LLC, while progressing its lead ADHD drug candidate, CTx-1301, towards an anticipated NDA submission by early August 2025.

Cingulate Inc. has filed an amendment to its Form S-1 registration statement to register an additional 1,500,000 shares for resale by Lincoln Park Capital, potentially raising up to $4.7 million.

Cingulate Inc. filed an amendment to its registration statement to correct a typographical error in the auditor consent filed as an exhibit.

Cingulate Inc. has filed a registration statement for the resale of up to 1,500,000 shares of its common stock by Lincoln Park Capital Fund, LLC.

Cingulate Inc. has filed a registration statement for the resale of up to 1,000,000 shares of its common stock by Lincoln Park Capital Fund, LLC, as part of a previously established purchase agreement.

Falcon Creek Capital Advisor and affiliated funds increase their beneficial ownership in Cingulate Inc. to 28.50% following stockholder approval of a private placement.

Cingulate Inc. announced an $11 million private placement of common stock, preferred stock, and warrants, granting significant ownership and board representation to Falcon Creek and Ginkgo Capital.